<DOC>
	<DOCNO>NCT02287272</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetic interaction CHF5993 ( pressurize metered-dose inhaler ( pMDI ) administer Cimetidine ( probe inhibitor organic cation transport kidney ) , compare systemic exposure ( AUC0-t ) Glycopyrronium Bromide ( GB ) , single dose fix combination CHF 5993 pMDI administer alone steady-state Cimetidine</brief_summary>
	<brief_title>Drug-drug Interaction Study CHF5993 With Cimetidine</brief_title>
	<detailed_description>safety tolerability study treatment base evaluation vital sign , electrocardiograms clinical laboratory assessment also evaluate .</detailed_description>
	<mesh_term>Cimetidine</mesh_term>
	<criteria>1 . Subject 's write informed consent obtain prior studyrelated procedure ; 2 . Male female healthy volunteer age 1845 year inclusive ; 3 . Male subject female partner childbearing potential : partner must willing use ( least ) one reliable method contraception ( see exclusion criterion n.1 details* ) time dose administration end study . Male subject must donate sperm 90 day last dose study drug . Male subject partner nonchildbearing potential require use contraception ; 4 . Able understand study procedure , risk involve ability train correctly use device ; 5 . Body Mass Index ( BMI ) 18.0 30.0 kg/m2 inclusive ; 6 . A serum creatinine within normal range ( 0,71,2 mg/dL ) eGFR &gt; 80 mL/min/1.73 m2 ; 7 . Non exsmokers smoke &lt; 5 pack year ( packyears = number cigarette pack per day time number year ) stop smoke &gt; 1 year ; 8 . Good physical mental status , determine basis medical history general clinical examination ; 1 . Female subject : pregnant lactate woman woman physiologically capable become pregnant ( i.e . woman childbearing potential ) UNLESS meet follow definition postmenopausal : 12 month natural ( spontaneous ) document amenorrhea willing use one follow reliable *methods contraception : 1. surgical sterilization ( e.g . bilateral tubal ligation , hysterectomy female ; vasectomy male ) 2. hormonal contraception ( implantable , patch , oral ) , intrauterine device ( IUD ) intrauterine system ( IUS ) 3. barrier method ( male female condom , diaphragm , sponge , cervical cap ) . 2 . Blood donation ( equal 450 ml ) blood loss le 8 week inhalation study medication ; 3 . Positive HIV1 HIV2 serology ; 4 . Positive result Hepatitis serology indicate acute chronic Hepatitis B Hepatitis C ; 5 . History substance abuse drug abuse within 12 month prior screen visit positive urine drug screen screen ; 6 . An abnormal triplicate 12lead ECG ( QRS &gt; 120 msec , PR &gt; 220 msec , HR &lt; 40 bpm , HR &gt; 110 bpm ) screen randomization ; 7 . Subjects whose electrocardiogram ( 12lead ECG ) show QTcF &gt; 450 m male &gt; 470 female screen randomization ; 8 . Subjects whose DBP high 90 mmHg SBP high 140 mmHg screen randomization ; 9 . Subjects receive investigational new drug , participate clinical study within last 8 week screen ; 10 . History hypersensitivity M3 Antagonists , Î²2agonist , corticosteroid excipients contain formulation use trial ; 11 . Treatment within previous 3 month screen visit end study procedure last treatment period drug know welldefined potential hepatotoxicity ( e.g . isoniazide , nimesulide , ketoconazole ) ; 12 . Subjects refuse abstain alcohol xanthine contain food beverage grapefruit contain food beverages 48 hour prior intake study medication end confinement clinical centre ; 13 . Heavy caffeine drinker ( &gt; 5 cup glass caffeinated beverage e.g. , coffee , tea , cola per day ) ; 14 . Subjects positive urine test cotinine screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>COPD- cimetidine- drug-drug interaction</keyword>
</DOC>